Blauvelt, A., Warren, R., Reich, K., Brock, F., Fierens, F., Ciaravino, V. and Lebwohl, M. 2020. Durability of DLQI Improvements Among Patients with Moderate to Severe Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2). SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s80. DOI:https://doi.org/10.25251/skin.4.supp.80.